SCHEMBL20181666

SCHEMBL20181666

CCc1nc2cnccn2c1C(=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 5/20 0.43
GAA P10253 6/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP19A1 P11511 6/20 0.40
ESR1 P03372 4/20 0.37
HPGD P15428 4/20 0.35
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 2/20 0.35
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
ALOX15 P16050 1/20 0.35
SYK P43405 1/20 0.34
ESR2 Q92731 2/20 0.34
LMNA P02545 2/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.33
ABL1 P00519 1/20 0.33
KIT P10721 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181578 0.87 CYP19A1 (0.46) MAPTALDH1A1GAANPSR1CYP19A1
SCHEMBL18629834 0.82 MAPK1 (0.50) ALDH1A1GAANPSR1HPGDHSD17B10
SCHEMBL20181563 0.82 SLC22A12 (0.39) MAPTCYP19A1ESR1HPGDESR2
SCHEMBL20181579 0.82 SLC22A12 (0.37) MAPTALDH1A1GAANPSR1ESR1
SCHEMBL15760437 0.80 GAA (0.37) MAPTALDH1A1GAAHPGDHSD17B10
SCHEMBL15760438 0.78 MAPK1 (0.48) MAPTALDH1A1GAAHPGDHSD17B10
SCHEMBL20181565 0.77 SLC22A12 (0.43) ALDH1A1NPSR1HPGDALOX15LMNA
SCHEMBL18357422 0.76 DAPK3 (0.41) MAPTALDH1A1GAAHPGDHSD17B10
SCHEMBL20181614 0.75 ALDH1A1 (0.50) MAPTALDH1A1GAACYP19A1ESR1
SCHEMBL20181584 0.74 MAPK1 (0.48) MAPTGAAESR1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 MAPT 433/4885ALDH1A1 356/4885GAA 378/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 MAPT 433/4885ALDH1A1 356/4885GAA 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.